Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study
Objective: To assess cognitive functioning in adolescents (12–17 years old) with schizophrenia during open-label treatment with paliperidone extended-release (pali ER). Methods: In this exploratory analysis, adolescents treated with pali ER (oral, flexibly dosed, 1.5–12 mg/day) underwent cognitive a...
Main Authors: | Gahan Pandina, Isaac Nuamah, Timothy Petersen, Jaskaran Singh, Adam Savitz, David Hough |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-06-01
|
Series: | Schizophrenia Research: Cognition |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2215001319300289 |
Similar Items
-
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
by: Mathews M, et al.
Published: (2018-10-01) -
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
by: Mathews M, et al.
Published: (2019-05-01) -
Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
by: Savitz AJ, et al.
Published: (2019-02-01) -
A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
by: Coppola Danielle, et al.
Published: (2012-03-01) -
Safety and Efficacy of Paliperidone Extended-Release in Acute and Maintenance Treatment of Schizophrenia
by: Edoardo Spina, et al.
Published: (2011-02-01)